With decades in gene ther­a­py un­der his belt, Ronald Crys­tal launch­es new ven­ture with up to 18 can­di­dates in the pipe

5 years ago
Financing
Startups

Al­ny­lam nears FDA fil­ing for 4th RNAi ther­a­py vutrisir­an af­ter late-stage da­ta back use in pro­tein mis­fold­ing ...

5 years ago
R&D

Gary Glick, Kei­th Fla­her­ty now have $270M to re­al­ize their vi­sion for Pre­ci­sion On­col­o­gy 2.0 — we'll just have to ...

5 years ago
Financing
Startups

Were­wolf pre­pares to bare its teeth in 1st tri­al for tar­get­ed cy­tokine tu­mor fight­ers with new round of in­vestor cash

5 years ago
Financing

Bris­tol My­ers Squibb ices li­cens­ing pact with Ar­se­nal­Bio to draft its de­sign­er T cells in­to the sol­id tu­mor fight

5 years ago
Deals
R&D

Abcuro will take an an­ti-KL­RG1 an­ti­body in­to the clin­ic with new fund­ing, and has big plans for an­oth­er

5 years ago
Startups

Covid-19 roundup: Cure­Vac finds big vac­cine part­ner in Bay­er; Slaoui will stay on as Biden con­sul­tant

5 years ago
Coronavirus

John Hood has found an­oth­er mis­fit drug to love — and bring back from the dead

5 years ago
R&D

EX­CLU­SIVE: Zai Lab’s Saman­tha Du scoops up Chi­na rights to an au­toim­mune drug with a hefty $175M li­cens­ing deal — ...

5 years ago
Deals

Fac­tor Bio­science spins out a new cell ther­a­py play­er with eyes on the clin­ic with­in 2 years

5 years ago
Startups

News brief­ing: Dew­point scores an­oth­er Big Phar­ma deal, this time with Pfiz­er; Kite joins forces with Ox­ford ...

5 years ago
News Briefing

Af­ter an up-and-down year, Nek­tar watch­es de­vel­op­ment head Wei Lin walk away as it pur­sues pipeline re­bound

5 years ago
People

Imara at­tempts to spin weak da­ta in­to an 'en­cour­ag­ing' re­sult — but in­vestors aren't hav­ing it

5 years ago
R&D

As­traZeneca's Farx­i­ga gets rough FDA re­view date for ground­break­ing move in­to chron­ic kid­ney dis­ease

5 years ago
FDA+

New year, new me: Pfiz­er aban­dons icon­ic 'blue pil­l' lo­go in fa­vor of sleek­er — if more am­bigu­ous — new de­sign

5 years ago
Pharma

So why is Alex­ion pay­ing $100M for a PRV as As­traZeneca lines up their $39B buy­out?

5 years ago
Deals
Pharma

Au­to­lus buck­les down, chop­ping 20% of staff and seek­ing part­ner for a lead CAR-T pro­gram

5 years ago
People

'N of 1' ther­a­pies ad­dressed in draft FDA guid­ance

5 years ago
FDA+

Tim Lu’s quest to break new cell ther­a­py ground with gene cir­cuits gets Bay­er’s back­ing in a big new fi­nanc­ing ...

5 years ago
Financing

Covid-19 roundup: EMA rec­om­mends Mod­er­na vac­cine for au­tho­riza­tion; Wood­cock re­turns to FDA as Hahn ad­vi­sor — ...

5 years ago
Coronavirus

Roche isn’t done lin­ing up new col­lab­o­ra­tions in the hot field of drug­ging RNA. Here’s one more

5 years ago
Deals

With lessons learned from Vor, Sid­dhartha Mukher­jee takes a dif­fer­ent route to tar­get sol­id tu­mors with start­up ...

5 years ago
Financing
Startups

Eliz­a­beth Nabel steps down as pres­i­dent of Brigham and Wom­en's Hos­pi­tal to team up with hus­band's biotech joint — ...

5 years ago
People

Ab­b­Vie eyes Hu­mi­ra match­ing move in­to pso­ri­at­ic arthri­tis for im­munol­o­gy fol­low-up Skyrizi

5 years ago
R&D
First page Previous page 759760761762763764765 Next page Last page
A service from the Financial Times